Seagen Inc (SGEN)

Etorro trading 970x250
Seagen Inc (SGEN) Logo

About Seagen Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. Address: 21823 30th Drive SE, Bothell, WA, United States, 98021

Seagen Inc News and around…

Latest news about Seagen Inc (SGEN) common stock and company :

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
23 May, 2022 FinancialContent

Seagen Inc(NASDAQ: SGEN)announced topline resultsfrom phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in ...

Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
23 May, 2022 FinancialContent

Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical trial investigating TUKYSA® (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). Data from this trial will form the basis of a planned supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) under the FDA’s Accelerated Approval Program. Merck, known as MSD outside the U.S. and Canada, is commercializing TUKYSA in regions outside of the U.S., Canada and Europe and plans to discuss these results with health authorities as it continues to accelerate the filing of TUKYSA in its territory.

Comparing XRP Versus Seattle Genetics Reveals New High
17 May, 2022 FinancialContent

Here at CryptocurrenciesChannel. om, we find it interesting to track various ETF and stock prices versus various digital assets over time.

Seagen CEO steps down after domestic violence arrest
16 May, 2022 Yahoo! Finance

Clay Siegall, who co-founded the Bothell-based biotech in 1998, first took a leave of absence from the company starting May 9, more than two weeks after his arrest.

Nasdaq 100 Movers: TEAM, SGEN
16 May, 2022 FinancialContent

In early trading on Monday, shares of Seagen topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.2%. Year to date, Seagen has lost about 9.4% of its value.

Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest
16 May, 2022 FinancialContent

Seagen Chief Executive Clay Siegall resigned Monday amid domestic violence allegations, and SGEN stock inched up.

2 Cheap Growth Stocks Near Their 52-Week Lows to Buy and Forget
16 May, 2022 FinancialContent

Buying these stocks on the dip could result in big returns for investors.

Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
16 May, 2022 FinancialContent

Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.

Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
16 May, 2022 FinancialContent

Seagen Inc. (Nasdaq: SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen’s Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found.

Nasdaq 100 Movers: PDD, SGEN
12 May, 2022 FinancialContent

In early trading on Thursday, shares of Seagen topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.0%. Year to date, Seagen has lost about 20.5% of its value.

Recent 10.0% pullback isn't enough to hurt long-term Seagen (NASDAQ:SGEN) shareholders, they're still up 90% over 5 years
12 May, 2022 Yahoo! Finance

Seagen Inc. ( NASDAQ:SGEN ) shareholders might be concerned after seeing the share price drop 17% in the last month. On...

103 Biggest Movers From Yesterday
11 May, 2022 FinancialContent

Gainers Biohaven Pharmaceutical Holding Company Ltd. (NASDAQ: BHVN) shares surged 68.4% to close at $140.00 on Tuesday. Pfizer ...

77 Stocks Moving In Tuesday's Mid-Day Session
10 May, 2022 FinancialContent

Gainers Biohaven Pharmaceutical Holding Company Ltd. (NASDAQ: BHVN) shares jumped 70.8% to $142.01. Pfizer Inc (NYSE: PFE) will ...

Nasdaq 100 Movers: MRNA, SGEN
10 May, 2022 FinancialContent

In early trading on Tuesday, shares of Seagen topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.5%. Year to date, Seagen has lost about 22.9% of its value.

Seagen CEO goes on leave amid domestic violence allegations
09 May, 2022 Yahoo! Finance

Seagen Chief Medical Officer Roger Dansey is taking over as interim CEO for the company, which is conducting an investigation with an independent law firm.

Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence
09 May, 2022 FinancialContent

The Board of Directors ofSeagen Inc(Nasdaq: SGEN) announced that its long-time president, CEO, and chairman Clay Siegall, ...

Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim
09 May, 2022 FinancialContent

Seagen CEO Clay Siegall was placed on leave after a domestic abuse allegation, the biotech company said Monday as SGEN stock dropped.

Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
09 May, 2022 FinancialContent

The Board of Directors of Seagen Inc. (Nasdaq: SGEN) today announced that President, CEO and Chairman Clay Siegall, Ph.D. is on a leave of absence. The company is aware of an alleged incident of domestic violence that occurred recently at Dr. Siegall’s home. Dr. Siegall has denied these allegations and has informed the company that he is engaged in a divorce. The Board of Directors has formed a committee of independent directors and is conducting a thorough investigation with the assistance of an independent law firm. Roger Dansey, M.D., Seagen’s Chief Medical Officer since 2018, has been appointed Interim CEO.

3 Unstoppable Stocks to Buy in May
07 May, 2022 FinancialContent

These big drugmakers should be long-term winners.

Looking Into Seattle Genetics's Return On Capital Employed
04 May, 2022 FinancialContent

According to Benzinga Pro data, during Q1, Seattle Genetics (NASDAQ:SGEN) posted sales of $426.46 million. Earnings were up 21.84%, but ...

4 Healthcare Funds With "Double Discounts"
01 May, 2022 FinancialContent

There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look at some opportunities in the healthcare sector.

Expert Ratings for Seagen
29 Apr, 2022 FinancialContent

Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings: Bullish Somewhat ...

Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
29 Apr, 2022 FinancialContent

FollowingSeagen Inc's(NASDAQ: SGEN) 1Q22 earnings release,RBC Capital Marketsis encouraged by the ...

Seagen Inc. (SGEN) Q1 2022 Earnings Call Transcript
29 Apr, 2022 FinancialContent

SGEN earnings call for the period ending March 31, 2022.

Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates
28 Apr, 2022 Yahoo! Finance

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 24.49% and 4.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Recap: Seagen Q1 Earnings
28 Apr, 2022 FinancialContent

Seagen (NASDAQ:SGEN) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:05 PM. Here's what investors need to know ...

Seagen Reports First Quarter 2022 Financial Results
28 Apr, 2022 FinancialContent

Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline.

Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
28 Apr, 2022 FinancialContent

Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its expanding pipeline of marketed and investigational therapies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022 in Chicago. The accepted abstracts demonstrate the growth of Seagen’s portfolio and clinical progress across multiple cancer types, including cervical and urothelial cancers and pediatric and adult Hodgkin lymphoma. Groundbreaking overall survival data for Stage III/IV Hodgkin lymphoma patients who were treated with ADCETRIS® (brentuximab vedotin) as part of a first-line therapy combination will be detailed in one of three oral presentations for the antibody-drug conjugate medicine.

Earnings Scheduled For April 28, 2022
28 Apr, 2022 FinancialContent

Companies Reporting Before The Bell • PBF Energy (NYSE:PBF) is projected to report quarterly earnings at $0.26 per ...

Construction underway on Seagen biomanufacturing facility in Everett
22 Apr, 2022 Yahoo! Finance

The Bothell-based company expects the 270,000-square-foot project to open in 2024 and employ up to 200 workers.

Seagen Inc (SGEN) is a NASDAQ Common Stock listed in , ,

970x250